Precede Biosciences
Eve Kretschmer currently serves as the Executive Director of Oncology R&D Strategy at AstraZeneca, a position held since July 2024. Previously, Eve held the role of VP of Corporate Development at Precede Biosciences from February 2023 to July 2024, and prior to that, was the Head of Corporate Strategy & Development at Generate Biomedicines, Inc. Eve has extensive experience at bluebird bio, where multiple roles, including VP of Strategy & Transformation and VP of Commercial Strategy & Operations, were undertaken. Prior consulting roles include positions at Boston Consulting Group and Booz & Company. Eve's career began in strategy at Lake Partners Strategy Consultants and Intellectual Ventures, contributing to significant licensing deals. Educational credentials include an MBA from Columbia Business School with a focus on Healthcare and Pharmaceutical Management, as well as a BA in Neuroscience from Dartmouth College.
This person is not in any teams
This person is not in any offices
Precede Biosciences
1 followers
We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test uncovers actionable disease-defining transcriptional biology. Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.